Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis

Annals of Hematology

Volumn 93, Issue 2, 2014, Pages 279-285

  Hoffmann, Joerg Christian ^a   Stabla, Kathleen ^a   Burchert, Andreas ^a   Volkmann, Thorsten ^a   Bornhäuser, Martin ^b   Thiede, Christian ^b   Neubauer, Andreas ^a   Brendel, Cornelia ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; CD34; Chimerism

Indexed keywords

CD34 ANTIGEN;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; BLOOD; FEMALE; FOLLOW UP; HISTOCOMPATIBILITY; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHYSIOLOGIC MONITORING; PROCEDURES; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTIGENS, CD34; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA;

EID: 84895058987     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1961-4     Document Type: Article

References (23)

1. Cornelissen JJ, van Putten WL, Verdonck LF et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 109:3658-3666
2. Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361
3. Chang C, Storer BE, Scott BL et al (2007) Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110:1379-1387
4. Kern W, Haferlach C, Haferlach T et al (2008) Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 112:4-16
5. Thiede C, Bornhauser M, Oelschlagel U et al (2001) Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 15:293-302
6. Lange T, Hubmann M, Burkhardt R et al (2011) Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25:498-505
7. Bornhauser M, Oelschlaegel U, Platzbecker U et al (2009) Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 94:1613-1617
8. Schmid C, Schleuning M, Aschan J et al (2004) Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 18:1430-1433
9. Platzbecker U, Wermke M, Radke J et al (2011) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26(3):381-389
10. Bader P, Willasch A, Klingebiel T (2008) Monitoring of post-transplant remission of childhood malignancies: is there a standard? Bone Marrow Transplant 42(Suppl 2):S31-S34
11. Thiede C, Lutterbeck K, Oelschlagel U et al (2002) Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. Ann Hematol 81(Suppl 2):S27-S28
12. Scheffold C, Kroeger M, Zuehlsdorf M et al (2004) Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis. Leukemia 18:2048-2050
13. Martino R, Iacobelli S, Brand R et al (2006) Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846
14. Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474
15. Swerdlow SH, Campo E, Harris NL et al (2008) In: Campo E (ed) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
16. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
17. Levine JE, Braun T, Penza SL et al (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20:405-412
18. Collins RH Jr, Shpilberg O, Drobyski WR et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444
19. Eapen M, Giralt SA, Horowitz MM et al (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34:721-727
20. Lubbert M, Bertz H, Wasch R et al (2010) Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627-632
21. Goodyear OC, Dennis M, Jilani NY et al (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119:3361-3369
22. Metzelder S, Wang Y, Wollmer E et al (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567-6571
23. Metzelder SK, Schroeder T, Finck A et al (2012) High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 26(11):2353-2359